Cargando…
Cancer biomarkers for targeted therapy
Tumor-associated antigens (TAA) or cancer biomarkers are major targets for cancer therapies. Antibody- based agents targeting the cancer biomarkers include monoclonal antibodies (MoAbs), radiolabeled MoAbs, bispecific T cell engagers, and antibody-drug conjugates. Antibodies targeting CD19, CD20, CD...
Autor principal: | Liu, Delong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857213/ https://www.ncbi.nlm.nih.gov/pubmed/31807308 http://dx.doi.org/10.1186/s40364-019-0178-7 |
Ejemplares similares
-
Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials
por: Hsueh, Chung-Tsen, et al.
Publicado: (2013) -
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
por: Liu, Delong
Publicado: (2019) -
Cell therapy must be regulated as medicine
por: Li, Zihai, et al.
Publicado: (2016) -
PHIPing along: Evolution of PHIP as a cancer biomarker and a target for therapy
por: Kashani-Sabet, Mohammed, et al.
Publicado: (2018) -
Recent Advances in Carcinogenesis Transcription Factors: Biomarkers and Targeted Therapies
por: Bode, Ann M., et al.
Publicado: (2023)